Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Bex

Showing results (241-250 of 332) with videos related to

Pageof 34
Sort By:
The Journal of Urology|November 25, 2015
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?Daan J Reesink, Elisabeth E Fransen van de Putte, Erik Vegt, et al.
European Urology|October 17, 2022
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines PanelUmberto Capitanio, Jens Bedke, Laurence Albiges, et al.
BMJ Open|June 14, 2019
Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing <b>NE</b>phron <b>S</b>paring <b>T</b>reatment (NEST) for small renal massesJoana B Neves, David Cullen, Lee Grant, et al.
EJNMMI Research|December 5, 2018
An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumorsTeele Kuusk, Maarten L Donswijk, Renato A Valdés Olmos, et al.
European Urology|December 11, 2017
Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal CancerThomas Powles, Laurence Albiges, Michael Staehler, et al.
Trials|March 21, 2026
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trialDiana Johnson, Ruth Thomas, Seonaidh Cotton, et al.
European Urology Oncology|September 26, 2024
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future DirectionsLaura Marandino, Riccardo Campi, Daniele Amparore, et al.
Applied Health Economics and Health Policy|May 19, 2021
How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, EnglandCaroline S Clarke, Cecilia Vindrola-Padros, Claire Levermore, et al.
Applied Health Economics and Health Policy|July 22, 2022
Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences AnalysisCaroline S Clarke, Mariya Melnychuk, Angus I G Ramsay, et al.
Journal of Health Services Research & Policy|April 26, 2022
Loss associated with subtractive health service change: The case of specialist cancer centralization in EnglandGeorgia B Black, Victoria J Wood, Angus I G Ramsay, et al.
Pageof 34

Showing results (241-250 of 332) with videos related to

Sort By:
Pageof 34
The Journal of Urology|November 25, 2015
Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography-Should Patients Receive Further Evaluation?Daan J Reesink, Elisabeth E Fransen van de Putte, Erik Vegt, et al.
European Urology|October 17, 2022
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making: Proposal from the European Association of Urology Guidelines PanelUmberto Capitanio, Jens Bedke, Laurence Albiges, et al.
BMJ Open|June 14, 2019
Protocol for a feasibility study of a cohort embedded randomised controlled trial comparing <b>NE</b>phron <b>S</b>paring <b>T</b>reatment (NEST) for small renal massesJoana B Neves, David Cullen, Lee Grant, et al.
EJNMMI Research|December 5, 2018
An analysis of SPECT/CT non-visualization of sentinel lymph nodes in renal tumorsTeele Kuusk, Maarten L Donswijk, Renato A Valdés Olmos, et al.
European Urology|December 11, 2017
Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal CancerThomas Powles, Laurence Albiges, Michael Staehler, et al.
Trials|March 21, 2026
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trialDiana Johnson, Ruth Thomas, Seonaidh Cotton, et al.
European Urology Oncology|September 26, 2024
Neoadjuvant and Adjuvant Immune-based Approach for Renal Cell Carcinoma: Pros, Cons, and Future DirectionsLaura Marandino, Riccardo Campi, Daniele Amparore, et al.
Applied Health Economics and Health Policy|May 19, 2021
How to Cost the Implementation of Major System Change for Economic Evaluations: Case Study Using Reconfigurations of Specialist Cancer Surgery in Part of London, EnglandCaroline S Clarke, Cecilia Vindrola-Padros, Claire Levermore, et al.
Applied Health Economics and Health Policy|July 22, 2022
Cost-Utility Analysis of Major System Change in Specialist Cancer Surgery in London, England, Using Linked Patient-Level Electronic Health Records and Difference-in-Differences AnalysisCaroline S Clarke, Mariya Melnychuk, Angus I G Ramsay, et al.
Journal of Health Services Research & Policy|April 26, 2022
Loss associated with subtractive health service change: The case of specialist cancer centralization in EnglandGeorgia B Black, Victoria J Wood, Angus I G Ramsay, et al.
Pageof 34